Aligning Leadership with Strategic Goals at Altimmune
In a celebrated move, Altimmune, Inc. has officially appointed Jerry Durso as Chairman of its Board of Directors. With extensive commercial expertise, Mr. Durso's leadership comes during an exciting phase of development for Altimmune, particularly regarding its innovative drug pemvidutide, which targets metabolic dysfunction-associated steatohepatitis (MASH).
Succession Planning and Transition
The leadership change, effective August 12, 2025, marks a significant moment for the company as it transitions towards advanced clinical phases. Previously held by Mitchel Sayare, Ph.D., Mr. Durso's role will now support the company's aim of preparing for Phase 3 development of pemvidutide, a promising therapeutic for treating MASH. This strategic transition underscores the Board's ongoing evaluation of its leadership needs to align with evolving business goals.
Building on Past Success
Vipin K. Garg, Ph.D., President and CEO of Altimmune, expressed enthusiasm for Mr. Durso's appointment, emphasizing the impactful contributions he has already made since joining the Board earlier this year. “Jerry's adept understanding of commercial dynamics will be pivotal as we continue our journey in the clinical stage,” said Dr. Garg.
Innovative Therapeutics for Tomorrow
Altimmune is making significant strides in the biopharmaceutical landscape, focusing on developing novel peptide-based therapies for liver and cardiometabolic diseases. Pemvidutide stands out as a game changer—a GLP-1/glucagon dual receptor agonist designed specifically to combat conditions like MASH and obesity. The promising topline data from the IMPACT trial has fortified its potential, showcasing the necessity for adept leadership during this crucial phase.
Experience That Counts
Jerry Durso brings to his role a wealth of experience amassed over three decades in the life sciences sector. Before his appointment, he served as the CEO at Intercept Pharmaceuticals, where he played a critical role in developing the company’s rare liver disease portfolio, leading to its acquisition by Alfasigma. His previous positions at Sanofi also reflect a solid foundation in the pharmaceutical industry, demonstrating his capability to navigate corporate and commercial challenges effectively.
Commitment to Patients and Stakeholders
During this transitional period, Mr. Durso is committed to enhancing Altimmune’s strategies not only to advance pemvidutide but also to create sustainable value for all stakeholders involved. He recognizes the importance of supporting the patient community through access to innovative therapies—a mission integral to Altimmune's ethos.
Looking Ahead: Phase 3 Development
As Altimmune gears up for an End-of-Phase 2 Meeting with the FDA planned for the upcoming fourth quarter, the board’s renewed focus on corporate development is timely. Dr. Sayare's continued presence on the Board as an Independent Director ensures a blend of new leadership and established expertise, fostering a synergistic approach to the challenges ahead.
About Altimmune
Altimmune stands as a beacon of innovation in therapeutic development, focusing on addressing significant unmet needs in liver and cardiometabolic health. Pemvidutide, the company’s core program, exemplifies its commitment to pioneering effective treatments.
Frequently Asked Questions
Who is the new Chairman of Altimmune?
Jerry Durso has been appointed as the new Chairman of Altimmune's Board of Directors.
What is pemvidutide?
Pemvidutide is a novel peptide-based therapeutic designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and other related conditions.
How does Jerry Durso's experience benefit Altimmune?
Durso brings over 30 years of leadership experience in the life sciences, enhancing corporate strategies and guiding the company through clinical development phases.
What is Altimmune's focus?
Altimmune is dedicated to developing peptide-based therapeutics aimed at liver and cardiometabolic diseases, particularly through its lead program, pemvidutide.
What are the next steps for Altimmune?
The company is set to engage with the FDA for an End-of-Phase 2 Meeting, targeting advancements in the development of pemvidutide.
